| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO &President | Director | EVP Pharmaceutical Oper &Tech
3 companies
Cox John is a CEO &President at Dyne Therapeutics, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 9 buys and 11 sells.
Estimated insider holdings value: $11.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | DYN Dyne Therapeutics, Inc. | CEO &President | Sell | 2,662 | $20.72 | $55,156.64 | -1.3% | -25.0% | - | |
| Sep 5, 2025 | DYN Dyne Therapeutics, Inc. | CEO &President | Sell | 2,640 | $13.41 | $35,402.40 | -1.3% | +45.2% | - | |
| Jul 14, 2025 | DYN Dyne Therapeutics, Inc. | CEO &President | Buy | 100,000 | $9.11 | $911,000.00 | +70.3% | +57.5% | - | |
| Jun 5, 2025 | DYN Dyne Therapeutics, Inc. | CEO &President | Sell | 4,060 | $13.35 | $54,201.00 | -2.8% | -3.6% | - | |
| Mar 5, 2025 | DYN Dyne Therapeutics, Inc. | CEO &President | Sell | 4,061 | $11.83 | $48,041.63 | -2.7% | +8.9% | +24.8% | |
| Sep 4, 2024 | DYN Dyne Therapeutics, Inc. | CEO &President | Buy | 32,000 | $33.04 | $1,057,216.00 | +1,000% | -16.6% | -60.8% | |
| Mar 24, 2020 | RGEN Repligen Corp | Director | Sell | 1,858 | $96.72 | $179,705.76 | -66.8% | - | - | |
| Mar 18, 2020 | RGEN Repligen Corp | Director | Sale+OE | 26,736 | $95.27 | $2,547,035.16 | -69.8% | - | - | |
| Mar 4, 2020 | RGEN Repligen Corp | Director | Sale+OE | 10,000 | $93.39 | $933,900.00 | -78.2% | - | - | |
| Feb 24, 2020 | RGEN Repligen Corp | Director | Sell | 4,455 | $92.81 | $413,454.80 | -31.0% | - | - |